A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life.
Can routinely collected primary care data drive life sciences investment in the UK? – Pharmaceutical Technology
By effectively harnessing this globally unparalleled and extensive health dataset, we have an opportunity to attract and engage global life sciences companies who are looking